AB Science S.A. (ABSCF)
| Previous close | 17.15 |
| Open | 17.66 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 17.66 - 18.40 |
| 52-week range | 8.65 - 26.70 |
| Volume | 500 |
| Avg. volume | 584 |
| Market cap | 759.606M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.54 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
PRESS RELEASE AB SCIENCE TO PRESENT RESULTS FROM ITS PHASE III AB09004 STUDY IN MILD TO MODERATE ALZHEIMER’S DISEASE AT THE WORLD'S LARGEST CONFERENCE FOR ALZHEIMER’S AND DEMENTIA RESEARCH (AAIC 2021) Paris, 22 July, 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC) (July
- Globe Newswire
AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
PRESS RELEASE PUBLICATION IN THE WORLD-RENOWNED JOURNAL SCIENCE CONFIRMS POTENTIAL OF MASITINIB AS A TREATMENT OF COVID-19 WITH ANTI-VIRAL ACTIVITY AGAINST SARS-COV-2 AND ALL TESTED VARIANTS OF CONCERN MASITINIB EFFECTIVELY REDUCED SARS-COV-2 VIRAL LOAD IN VIVO, REDUCING INFLAMMATORY SIGNATURES, AND SHOWED POTENTIAL BENEFITS FOR SURVIVAL AND CLINICAL SCORES Paris, 20 July, 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces publication of a peer-reviewed article titled ‘Ma
- Globe Newswire
AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
PRESS RELEASE LONG-TERM FOLLOW-UP OF 75 MONTHS SHOWED THAT MASITINIB EXTENDED SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS BY 25 MONTHS RELATIVE TO PLACEBO, PROVIDED THAT TREATMENT STARTS EARLY IN DISEASE COURSE. PUBLICATION OF LONG-TERM FOLLOW-UP SURVIVAL DATA IN THE PEER-REVIEWED JOURNAL THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS Paris, 19 July, 2021, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced publication of a paper titled ‘Long-term Survival Analysis of Masitinib in
